HERON THERAPEUTICS INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
HERON THERAPEUTICS INC. - More news...
HERON THERAPEUTICS INC. - More news...
- Heron Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
- Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV)
- Heron Therapeutics Announces $76.5 Million Private Placement Financing
- Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Highlights Recent Corporate Updates
- Heron Therapeutics to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
- Heron Therapeutics Announces Restructuring and Cost Reduction Plan to Address Market Dynamics and Prepare for Long-Term Sustainability
- Heron Therapeutics Announces Publication Showing ZYNRELEF® as the Foundation of a Perioperative Non-Opioid Multimodal Analgesic Regimen Reduced Severe Pain and Opioid Use in Patients Undergoing Total Knee Arthroplasty
- Heron Therapeutics to Present at the 2022 Jefferies Global Healthcare Conference
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Heron Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
- Heron Therapeutics Presents ZYNRELEF® Data at the Society for Obstetric Anesthesia and Perinatology 54th Annual Meeting
- Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2022 and Highlights Recent Corporate Updates
- Heron Therapeutics to Report First Quarter 2022 Financial Results on Monday, May 9, 2022
- Heron Therapeutics to Present at the 21st Annual Virtual Needham Healthcare Conference
- Heron Therapeutics Secures Pass-through Payment Status for ZYNRELEF® from Centers for Medicare & Medicaid Services, Expanding Separate Reimbursement into the Hospital Outpatient Setting of Care
- Heron Therapeutics Announces Approval of ZYNRELEF® by Health Canada for the Management of Postoperative Pain
- Heron Therapeutics to Present at 42nd Annual Cowen Healthcare Conference
- Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2021 and Highlights Recent Corporate Updates
- Heron Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
- Heron Therapeutics Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF®
- Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA
- Heron Therapeutics to Present at Upcoming Investor Conferences
- Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021 and Highlights Recent Corporate Updates
- Heron Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 3, 2021
- Heron Therapeutics Announces Filing of a Supplemental New Drug Application for Significant Expansion of ZYNRELEF® Indication Statement Based on Successful Outcome of FDA Type C Meeting
- Heron Therapeutics to Present at the 2021 Cantor Virtual Global Healthcare Conference
- Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021 and Highlights Recent Corporate Updates
- Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients Experiencing an Opioid-free Recovery
- Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™
- Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF™
- Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative Pain for up to 72 Hours